U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07704801) titled 'CDK4/6 Inhibitors in Metastatic HR-Positive Breast Cancer' on July 09.
Brief Summary: This study is a retrospective review aimed at evaluating the real-world outcomes and clinical efficacy of CDK4/6 inhibitors (such as Palbociclib, Ribociclib, or Abemaciclib) in patients diagnosed with metastatic luminal A and luminal B breast cancer. The study will assess how patients responded to these treatments based on their specific breast cancer subtype (Luminal A vs. Luminal B) by reviewing their medical records.
Study Start Date: Jan. 01, 2021
Study Type: OBSERVATIONAL
Condition:
Metastatic Breast Cancer
Intervention:
DRUG: CDK4/6 inh...